Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-089153
Filing Date
2026-08-13
Accepted
2026-08-13 16:31:11
Documents
60
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0301223-10q_cadrenal.htm   iXBRL 10-Q 667323
2 CERTIFICATION ea030122301ex31-1.htm EX-31.1 10551
3 CERTIFICATION ea030122301ex31-2.htm EX-31.2 10009
4 CERTIFICATION ea030122301ex32-1.htm EX-32.1 4071
5 CERTIFICATION ea030122301ex32-2.htm EX-32.2 3740
  Complete submission text file 0001213900-26-089153.txt   4441075

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20260630.xsd EX-101.SCH 48524
7 XBRL CALCULATION FILE cvkd-20260630_cal.xml EX-101.CAL 26782
8 XBRL DEFINITION FILE cvkd-20260630_def.xml EX-101.DEF 127648
9 XBRL LABEL FILE cvkd-20260630_lab.xml EX-101.LAB 337995
10 XBRL PRESENTATION FILE cvkd-20260630_pre.xml EX-101.PRE 259204
64 EXTRACTED XBRL INSTANCE DOCUMENT ea0301223-10q_cadrenal_htm.xml XML 508543
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41596 | Film No.: 261274073
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)